Vertex entered the second half of 2025 with clearly visible growth momentum and a portfolio expansion that goes beyond traditional cystic fibrosis treatments. The company confirms that it can not only maintain its dominant market position, but also systematically build new pillars of growth - from gene therapies to innovative approaches to pain management. Revenue growth, strong profitability and stable cash flow reinforce the company's position as one of today's best-managed biotech players.

At the same time, a strategy combining cutting-edge research, thoughtful acquisitions and prudent financial policies is proving to bear fruit. Vertex is benefiting from the success of its new therapies CASGEVA, JOURNAVX and ALYFTREK, which have already contributed significantly to sales and patient base growth in the second quarter. At the same time, the company has maintained a high level of investment in development, with a strong balance sheet and more than $12 billion in cash, giving it ample…